Where does GeneCentric Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), GeneCentric Therapeutics, Inc. ranks #28,841 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does GeneCentric Therapeutics, Inc. hold?

GeneCentric Therapeutics, Inc. holds 9 US utility patents granted between 2020 and 2025, spanning 6 technology areas.

What is GeneCentric Therapeutics, Inc.'s Innovation Score?

GeneCentric Therapeutics, Inc. has an Innovation Score of 34.0 out of 100 (46th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is GeneCentric Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for GeneCentric Therapeutics, Inc..

What does claim depth mean for GeneCentric Therapeutics, Inc.'s patents?

GeneCentric Therapeutics, Inc.'s patents average 10.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the GeneCentric Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

GeneCentric Therapeutics, Inc.

Q: What technology areas does GeneCentric Therapeutics, Inc. focus on?

GeneCentric Therapeutics, Inc.'s top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 9 patents, ranking #499 of 2,502 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Genecentric ranks #28,841 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 6 technology areas.

#28,841
of 49,997 US assignees by volume: 46th percentile
by Innovation Score (34.0/100): 10.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R28841 · US Corporation #28,841 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 9 grants
MID-PACK #28,841/49,997
PHOTO-FINISH Gatekeeper
CPC-NARROW C12Q · 6 areas
INNOV-THIN 34.0/100
CLAIMS-PAR 10.4 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Gatekeeper Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Genecentric’s 34.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (23%) Velocity 11.1 pts (33%) Breadth 8.7 pts (26%) Claim depth 6.3 pts (18%)

Qualcomm Incorporated · highest

85
GeneCentric… · this assignee

34
3D Lighting… · lowest

7

What this shows Genecentric's Innovation Score is 34.0/100 (46th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Genecentric?

Each dot is one of Genecentric’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Genecentric’s own 10.4 claims/patent is at or below the 18.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Genecentric vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Genecentric's grants concentrate

GeneCentric Therapeutics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2020. By volume, Genecentric sits between Gatekeeper Ltd. and Genesis Systems LLC.

Genecentric's three-year grant acceleration

GeneCentric Therapeutics, Inc. shows 5 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Gatekeeper

9
Geckobrands

9
Geerpres

9
Gems Sensors

9
Genelux

9
General Lasertron…

9
Generon (Shanghai)

9
Genesis Systems

9
Genecentric Thera… ◀

9

What this shows GeneCentric holds 9 patents at rank #28,871, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near GeneCentric

By rank, the assignees closest to #28,871 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in GeneCentric's primary technology class.

Genecentric's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 46th percentile higher than 46% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

GeneCentric Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	11.1%
2021	2	22.2%
2023	2	22.2%
2024	3	33.3%
2025partial year	1	11.1%

Which technologies does GeneCentric Therapeutics, Inc. patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 9

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C07K - Peptides 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C12Y - Enzymes 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

GeneCentric Therapeutics, Inc.'s patent record in context - here's where to go next.

GeneCentric Therapeutics, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 100% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #28,841 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare GeneCentric Therapeutics, Inc. against Gatekeeper Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.